NuviniAI Lab Reports Breakthrough Gains From AI-First Development Strategy - Nvni Group (NASDAQ:NVNI)

Nvni Group Ltd (NVNI) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 NUVINI NASDAQ: NVNI FOR IMMEDIATE RELEASE Nuvini Group Reports First Half 2026 Results: Operating Income of R$19.6 Million, Positive Operating Cash Flow, Net Loss Reduced 76% Gross margin expands to 68%; G&A down 25%; Company advances capital restructuring SÃO PAULO

Nvni Group Limited (Nasdaq: NVNI) said it is in the final stretch of acquiring a 51% controlling interest in a holding company for Beyondsoft’s U.S., Brazil and Singapore consulting/services business. The company expects pro forma FY2025 revenue of about $148M, serving 22,400+ customers. Nuvini cited Target incorporation, near-complete restructuring, shareholder approval, and renewal/assignment of a key client contract, with remaining regulatory and agreement steps pending.

Oppenheimer analyst Suraj Kalia reduced the price target for Boston Scientific (BSX) to $65 from $85, maintaining an Outperform rating. The firm also lowered its FY26 and FY27 estimates, citing a cybersecurity breach and competitive pressures in LAAC/EP.

Bitmine Immersion Technologies (BMNR) reports holding 5.98 million ETH tokens, representing 4.9% of total supply. The company's total crypto and cash holdings are $17.1 billion, nearing its 'Alchemy of 5%' goal. ETH has outperformed the S&P 500 by 6,519 basis points in Q3 2026.

Piper Sandler reduced its price target for Colgate-Palmolive (CL) to $95 from $98, citing cost pressures from elevated oil prices and inventory headwinds. The firm maintained an Overweight rating and a 2026 EPS estimate of $3.85, but lowered its 2027 EPS estimate to $4.12 from $4.23. CL trades at $87.47 with a P/E ratio of 34.6 and a gross profit margin of 60%. Other analysts have maintained positive outlooks, with RBC and UBS setting higher price targets.

KeyBanc raised its price target for Dycom Industries (NYSE:DY) to $429 from $423, citing growth outlook and meetings with management. The stock is down 48% from its 52-week high but is considered undervalued. Other analysts have mixed views, with UBS reiterating a Buy rating and Raymond James lowering its target. Dycom reported 38% revenue growth over the last year.